Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

Completed $200 million private placement post period
Phase 3 COPD clinical trials planned to start later this yearPilot clinical study in patients hospitalized with COVID-19 planned to start in the third quarter Conference Call Today at 9:00 am EDT / 2:00 pm BSTLONDON and RALEIGH, N.C., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (a??Verona Pharmaa?? or the a??Companya??), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces financial results for the three and six months ended JuneA30, 2020 and provides a corporate update.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »